STAAR Surgical Operating Income Over Time
| STAA Stock | USD 17.74 0.02 0.11% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out STAAR Surgical Performance and STAAR Surgical Correlation. Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of STAAR Surgical. If investors know STAAR will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive STAAR Surgical assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Quarterly Earnings Growth (0.10) | Earnings Share (1.96) | Revenue Per Share | Quarterly Revenue Growth 0.069 | Return On Assets |
The market value of STAAR Surgical is measured differently than its book value, which is the value of STAAR that is recorded on the company's balance sheet. Investors also form their own opinion of STAAR Surgical's value that differs from its market value or its book value, called intrinsic value, which is STAAR Surgical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because STAAR Surgical's market value can be influenced by many factors that don't directly affect STAAR Surgical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between STAAR Surgical's value and its price as these two are different measures arrived at by different means. Investors typically determine if STAAR Surgical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Meanwhile, STAAR Surgical's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Cross Equities Operating Income Analysis
Compare STAAR Surgical and related stocks such as Kestra Medical Techn, Pulse Biosciences, and Novocure Operating Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| KMTS | (29.3 M) | (29.3 M) | (29.3 M) | (29.3 M) | (29.3 M) | (29.3 M) | (29.3 M) | (29.3 M) | (29.3 M) | (29.3 M) | (32.7 M) | (80.4 M) | (80.4 M) | (85.1 M) | (106.4 M) | (95.7 M) | (100.5 M) |
| PLSE | (308.6 K) | (308.6 K) | (308.6 K) | (308.6 K) | (308.6 K) | (4.5 M) | (9.6 M) | (25.8 M) | (38 M) | (48 M) | (50 M) | (63 M) | (58.1 M) | (43.6 M) | (56.3 M) | (76.9 M) | (73.1 M) |
| NVCR | (64.5 M) | (64.5 M) | (64.5 M) | (64.5 M) | (80.2 M) | (104 M) | (115.3 M) | (39.3 M) | (33.7 M) | (914 K) | 30.4 M | (44.3 M) | (89.5 M) | (232.9 M) | (170.5 M) | (153.4 M) | (145.8 M) |
| AZTA | 2.5 M | 21.5 M | (8.5 M) | 4 M | 22.3 M | 19.5 M | 18.2 M | 34.4 M | 55.1 M | (27.5 M) | 3.6 M | (24 M) | (82.2 M) | (30 M) | (11.3 M) | (13 M) | (13.6 M) |
| BBNX | (65.8 M) | (65.8 M) | (65.8 M) | (65.8 M) | (65.8 M) | (65.8 M) | (65.8 M) | (65.8 M) | (65.8 M) | (65.8 M) | (65.8 M) | (65.8 M) | (65.8 M) | (35.9 M) | (45.3 M) | (71.7 M) | (75.3 M) |
| BLFS | (300 K) | (1.2 M) | (942.2 K) | (285.4 K) | (3.1 M) | (5 M) | (4.9 M) | (1.1 M) | 3.7 M | (781 K) | (3.3 M) | (35.2 M) | (5.9 M) | (70.8 M) | (7.1 M) | (6.4 M) | (6.7 M) |
| TERN | (18.5 M) | (18.5 M) | (18.5 M) | (18.5 M) | (18.5 M) | (18.5 M) | (18.5 M) | (18.5 M) | (18.5 M) | (70.2 M) | (37 M) | (49.9 M) | (62 M) | (102.6 M) | (101.9 M) | (91.7 M) | (96.3 M) |
| PGEN | (82.4 M) | (82.4 M) | (75.2 M) | (58 M) | (70 M) | (146.9 M) | (125.2 M) | (137.9 M) | (505.6 M) | (86.3 M) | (86.3 M) | (91.9 M) | (75.7 M) | (99.8 M) | (135 M) | (121.5 M) | (127.6 M) |
| ORIC | (22.5 M) | (22.5 M) | (22.5 M) | (22.5 M) | (22.5 M) | (22.5 M) | (22.5 M) | (22.5 M) | (22.4 M) | (28.6 M) | (74.2 M) | (78.9 M) | (91.8 M) | (110.8 M) | (142.9 M) | (128.6 M) | (122.2 M) |
STAAR Surgical and related stocks such as Kestra Medical Techn, Pulse Biosciences, and Novocure Operating Income description
Operating Income is the amount of profit realized from STAAR Surgical operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of STAAR Surgical is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.My Equities
My Current Equities and Potential Positions
| STAAR Surgical | STAA |
Specialization | Health Care, Health Care Equipment & Services |
| Business Address | 25510 Commercentre Drive, |
| Exchange | NASDAQ Exchange |
USD 17.74
Check out STAAR Surgical Performance and STAAR Surgical Correlation. For information on how to trade STAAR Stock refer to our How to Trade STAAR Stock guide.You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
STAAR Surgical technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.